

Luman Yu

Associate Attorney

lyu@gibsondunn.com

T: +86 10 6502 8525

Beijing

Luman Yu is an associate in the Beijing office of Gibson, Dunn & Crutcher LLP. She is a member of the firm's Mergers & Acquisitions and Private Equity Practice Groups. Luman advises corporates and investment funds on high-value, complex transactions, including cross-border M&A, buyouts, divestitures, joint ventures, and strategic and minority investments. Her practice also includes advising on shareholder activism and takeover defense matters.

Prior to joining Gibson Dunn, Luman practiced in the Washington, D.C. and Beijing offices of several leading U.S. law firms, where she advised on a broad range of cross-border transactions.

Luman received her Juris Doctor from the University of Pennsylvania Law School, graduating *cum laude*. She also received her Master of Laws from the University of Pennsylvania Law School, with distinction. She earned her Bachelor of Laws and Bachelor of Arts in Economics from Peking University.

Luman is admitted to practice in New York. She is native in Mandarin and fluent in English.

Representative Matters*

- HollySys Automation Technologies, a leading industrial automation and control systems company, on its USD1.66 billion contested take-private transaction by Ascendent Capital Partners. Awarded "Most Innovative Deals and Best Structured Finance Deal" at the FinanceAsia Achievement Awards, and "Deal of the Year" by China Business Law Journal.
- TPG on its KRW733 billion sale of Samhwa Co., Ltd., a leading Korean cosmetics-packaging manufacturer, to KKR. Shortlisted for "Exit of the Year - Mid Cap" at the AVCJ Private Equity & Venture Capital Awards.
- Sirio Pharma, a leading Chinese nutraceutical CDMO, on its acquisition of 71.41% of the interests in Best Formulations Inc., a California-based nutritional supplement manufacturer. Shortlisted for "M&A Deal of the Year" at The Asian Legal Business' Hong Kong Law Awards.
- Standard Industries Inc., a global industrial company with businesses in building materials and specialty chemicals, on its CAD229.9 million acquisition of FT Synthetics, Inc., a manufacturer of premium synthetic roofing underlayments, and its Chinese affiliate Qingdao Inno Tech Polymer Co., Ltd.
- Fusion Pharmaceuticals Inc., a U.S. clinical-stage oncology radiopharmaceutical company, on its acquisition of the intellectual property and assets related to the IPN-1087 radiopharmaceutical from Ipsen Pharma SAS, a global biopharmaceutical company headquartered in France, for consideration including an upfront equity payment and up to EUR417.5 million in potential milestone



Capabilities

Mergers and Acquisitions
Private Equity

Credentials

Education

University of Pennsylvania - 2018 Juris Doctor
University of Pennsylvania - 2016 Master of Laws (LL.M.)
Peking University - 2015 Bachelor of Laws (LL.B.)
Peking University - 2015 Bachelor of Arts

Admissions

New York Bar

payments.

- Merck & Co., Inc., a leading global biopharmaceutical company on:
 - The acquisition of Oncolmmune, a clinical-stage immunotherapy company, for a USD425 million upfront payment plus additional milestone payments.
 - The divestiture of The StayWell Company, a provider of health engagement and patient education solutions, to WebMD Health Corp.
 - The divestiture of Aptus Health, Inc., a global digital health-engagement company, to WebMD Health Corp.
 - The EUR2.1 billion acquisition of Antelliq Corporation, a French global leader in animal health and monitoring technologies.
- Simmons First National Corporation, a U.S. regional bank, on its USD435 million acquisition of The Landrum Company, a community bank headquartered in Missouri.

* Includes matters handled prior to joining Gibson Dunn.

Luman Yu

Associate Attorney

lyu@gibsondunn.com

T: +86 10 6502 8525

Beijing